Business Editors/Health/Medical Writers SYDNEY, Australia--(BUSINESS WIRE)--April 9, 2003 Results of Multi-Center Trial Presented at International Medical Meeting Gilead Sciences (Nasdaq:GILD) today announced 96-week results from a study of its oral antiviral dru...

Gilead Sciences, Inc. (Nasdaq:GILD), Foster City, Calif. has announced that the European Union's Committee for Proprietary Medicinal Products (CPMP CPMP - Canadian Project Management ProfessionalCPMP - Committee for Proprietary Medicinal ProductsCPMP - Core-Plus Math...

Tokyo, Japan, Aug 3, 2006 - (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry. Baraclude is an anti-viral action drug for treatment of chronic hepa...

- Record Full Year Total Revenues of $3.03 Billion, Up 49 Percent over 2005 -- Record Full Year Product Sales of $2.59 Billion, Up 43 Percent over 2005 -- Fourth Quarter Net Loss Per Share of $(3.62); Fourth Quarter Non-GAAP Net Income Per Share of $0.78, excluding...

Gilead Sciences, Inc.(Nasdaq: GILD), Foster City, Calif., has announced its results of operations for the quarter ended June 30, 2008. Total revenues for the second quarter of 2008 were $1.28 billion, up 22 percent compared to total revenues of $1.05 billion for ...

Business Editors; Energy & High-Tech Writers HOUSTON--(BUSINESS WIRE)--Nov. 12, 2001 Daniel Daniel, persons in the BibleDaniel, in the Bible.1 Prophet, central figure of the book of Daniel.2 See Chileab.3 Sealer of the covenant.Daniel, book of the BibleDan...

Safety: Adefovir is associated with several toxicities that warrant careful patient monitoring. (1,2) Due to treatment-limiting nephrotoxicity, all patients receiving adefovir need routine monitoring of renal function, especially patients who take other nephrotoxic dr...

Lamivudine was previously the only oral medication for chronic hepatitis B infection and had problems with rapid induction of viral resistance, which led to severe hepatitis flares in some affected patients. Tailoring therapy to those patients at increased risk of dis...

The article "Hepatitis B" in the January 1, 2004, issue (page 75) contained an error in the pricing of adefovir dipivoxil (Hepsera). On page 80, in Table 7, under the entry for adefovir dipivoxil, the cost of $528 is for one month of therapy, rather than one...

TABLE 1 Hepatitis B and C: Indications and Treatment Recommended treatment Agent Indications regimen * Hepatitis B virus ALT level >two times Interferon alfa-2b (HBV) ...